Home > Search Results: Zamora, Lurdes
  Search Tips
Advanced Search
Search collections:
Sort by: Display results: Output format:
Results overview: Found 12 records in 0.01 seconds.
Articles, 9 records found
Research literature, 3 records found
Articles 9 records found  
1.
17 p, 2.3 MB Analysis of Intratumoral Heterogeneity in Myelodysplastic Syndromes with Isolated del(5q) Using a Single Cell Approach / Acha, Pamela (Institut de Recerca contra la Leucèmia Josep Carreras) ; Xicoy, Blanca (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Mallo, Mar (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Manzanares Mileo, Ana (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Grau, Javier (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Marcé, Silvia (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Granada, Isabel (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Rodríguez-Luaces, Marta (ICO-Hospital Verge de la Cinta de Tortosa. Servei d'Hematologia) ; Diez-Campelo, María (Hospital Universitari de Salamanca. Servei d'Hematologia) ; Zamora, Lurdes (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Sole, F. (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Palomo Sanchís, Laura (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Fuster-Tormo, Francisco (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Universitat Autònoma de Barcelona
Myelodysplastic syndromes (MDS) are a heterogeneous group of hematological diseases. Among them, the most well characterized subtype is MDS with isolated chromosome 5q deletion (MDS del(5q)), which is the only one defined by a cytogenetic abnormality that makes these patients candidates to be treated with lenalidomide. [...]
2021 - 10.3390/cancers13040841
Cancers, Vol. 13 Núm. 4 (2021) , p. 841  
Detailed record - Creative Commons
2.
14 p, 4.1 MB Inhibition of inflammatory signaling in Pax5 mutant cells mitigates B-cell leukemogenesis / Isidro-Hernández, M. (Institute for Biomedical Research of Salamanca (IBSAL)) ; Mayado, A. (Servicio de Citometría. Departamento de Medicina. Biomedical Research Networking Centre on Cancer CIBER- CIBERONC (CB16/12/00400). Institute of Health Carlos III. and Instituto de Biología Molecular y Celular del Cáncer. CSIC/Universidad de Salamanca) ; Casado-García, A. (Institute for Biomedical Research of Salamanca (IBSAL)) ; Martínez-Cano, J. (Immune system development and function Unit. Centro de Biología Molecular Severo Ochoa (Consejo Superior de Investigaciones Científicas -Universidad Autónoma de Madrid)) ; Palmi, C. (Centro Ricerca Tettamanti. Dept of Medicine. University of Milan Bicocca) ; Fazio, G. (Centro Ricerca Tettamanti. Dept of Medicine. University of Milan Bicocca) ; Orfao, A. (Servicio de Citometría. Departamento de Medicina. Biomedical Research Networking Centre on Cancer CIBER- CIBERONC (CB16/12/00400). Institute of Health Carlos III. and Instituto de Biología Molecular y Celular del Cáncer. CSIC/Universidad de Salamanca) ; Ribera, Jordi (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Ribera, Jose-Maria (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Zamora, Lurdes (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Raboso-Gallego, J. (Institute for Biomedical Research of Salamanca (IBSAL)) ; Blanco, O. (Departamento de Anatomía Patológica. Universidad de Salamanca) ; Alonso-López, D. (Bioinformatics Unit. Cancer Research Center (CSIC-USAL)) ; De Las Rivas, J. (Bioinformatics and Functional Genomics Research Group. Cancer Research Center (CSIC-USAL)) ; Jiménez, R. (Departamento de Fisiología y Farmacología. Universidad de Salamanca) ; García Criado, F.J. (Departamento de Cirugía. Universidad de Salamanca) ; García Cenador, M.B. (Departamento de Cirugía. Universidad de Salamanca) ; Ramírez-Orellana, M. (Department of Pediatric Hematology and Oncology. Hospital Infantil Universitario Niño Jesús. Universidad Autónoma de Madrid) ; Cazzaniga, G. (Centro Ricerca Tettamanti. Dept of Medicine. University of Milan Bicocca) ; Cobaleda, C. (Immune system development and function Unit. Centro de Biología Molecular Severo Ochoa (Consejo Superior de Investigaciones Científicas -Universidad Autónoma de Madrid)) ; Vicente-Dueñas, C. (Institute for Biomedical Research of Salamanca (IBSAL)) ; Sánchez-García, I. (Institute for Biomedical Research of Salamanca (IBSAL)) ; Universitat Autònoma de Barcelona
PAX5 is one of the most frequently mutated genes in B-cell acute lymphoblastic leukemia (B-ALL), and children with inherited preleukemic PAX5 mutations are at a higher risk of developing the disease. [...]
2020 - 10.1038/s41598-020-76206-y
Scientific reports (Nature Publishing Group), Vol. 10 Núm. 1 (january 2020) , p. 19189  
Detailed record - Creative Commons
3.
11 p, 1.3 MB A novel targeted RNA-Seq panel identifies a subset of adult patients with acute lymphoblastic leukemia with BCR-ABL1-like characteristics / Sánchez, R. (Haematological Malignancies Clinical Research Unit. Spanish National Cancer Research Centre (CNIO)) ; Ribera, Jordi (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Morgades, Mireia (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Ayala, R. (Universidad Complutense de Madrid) ; Onecha, E. (Instituto de Investigación Hospital 12 Octubre (i+12)) ; Ruiz-Heredia, Y. (Hematology Department. Hospital Universitario 12 de Octubre) ; Juárez-Rufián, A. (Hematology Department. Hospital Universitario 12 de Octubre) ; de Nicolás, R. (Hematology Department. Hospital Universitario 12 de Octubre) ; Sánchez-Pina, J. (Hematology Department. Hospital Universitario 12 de Octubre) ; Vives Polo, Susana (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Zamora, Lurdes (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Mercadal, S. (Hematology Department. ICO - Hospital Duran i Reynals (Bellvitge)) ; Coll, R. (Hospital Universitari de Girona Doctor Josep Trueta) ; Cervera, M. (Hematology Department. ICO - Hospital Universitari Joan XXIII) ; García, Olga (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Ribera, Jose-Maria (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Martínez-López, J. (Universidad Complutense de Madrid) ; Universitat Autònoma de Barcelona
BCR-ABL1-like B-cell precursor acute lymphoblastic leukemia (BCP-ALL) remains poorly characterized in adults. We sought to establish the frequency and outcome of adolescent and adult BCR-ABL1-like ALL using a novel RNA-Seq signature in a series of patients with BCP-ALL. [...]
2020 - 10.1038/s41408-020-0308-3
Blood Cancer Journal, Vol. 10 Núm. 4 (january 2020) , p. 43  
Detailed record - Creative Commons
4.
11 p, 1.5 MB Comparison of flow-FISH and MM-qPCR telomere length assessment techniques for the screening of telomeropathies / Ferreira, M.S.V. (Department of Hematology. Oncology. Hemostaseology and Stem Cell Transplantation. Medical Faculty. RWTH Aachen University. University Hospital Aachen) ; Kirschner, M. (Department of Hematology. Oncology. Hemostaseology and Stem Cell Transplantation. Medical Faculty. RWTH Aachen University. University Hospital Aachen) ; Halfmeyer, I. (Department of Hematology. Oncology. Hemostaseology and Stem Cell Transplantation. Medical Faculty. RWTH Aachen University. University Hospital Aachen) ; Estrada, Natalia (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Xicoy, Blanca (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Isfort, S. (Department of Hematology. Oncology. Hemostaseology and Stem Cell Transplantation. Medical Faculty. RWTH Aachen University. University Hospital Aachen) ; Vieri, M. (Department of Hematology. Oncology. Hemostaseology and Stem Cell Transplantation. Medical Faculty. RWTH Aachen University. University Hospital Aachen) ; Zamora, Lurdes (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Abels, A. (Department of Hematology. Oncology. Hemostaseology and Stem Cell Transplantation. Medical Faculty. RWTH Aachen University. University Hospital Aachen) ; Bouillon, A.S. (Department of Hematology. Oncology. Hemostaseology and Stem Cell Transplantation. Medical Faculty. RWTH Aachen University. University Hospital Aachen) ; Begemann, M. (Institute of Human Genetics. Medical Faculty. RWTH Aachen University) ; Schemionek, M. (Department of Hematology. Oncology. Hemostaseology and Stem Cell Transplantation. Medical Faculty. RWTH Aachen University. University Hospital Aachen) ; Maurer, A. (Department of Hematology. Oncology. Hemostaseology and Stem Cell Transplantation. Medical Faculty. RWTH Aachen University. University Hospital Aachen) ; Koschmieder, S. (Department of Hematology. Oncology. Hemostaseology and Stem Cell Transplantation. Medical Faculty. RWTH Aachen University. University Hospital Aachen) ; Wilop, S. (Department of Hematology. Oncology. Hemostaseology and Stem Cell Transplantation. Medical Faculty. RWTH Aachen University. University Hospital Aachen) ; Panse, J. (Department of Hematology. Oncology. Hemostaseology and Stem Cell Transplantation. Medical Faculty. RWTH Aachen University. University Hospital Aachen) ; Brümmendorf, T.H. (Department of Hematology. Oncology. Hemostaseology and Stem Cell Transplantation. Medical Faculty. RWTH Aachen University. University Hospital Aachen) ; Beier, F. (Department of Hematology. Oncology. Hemostaseology and Stem Cell Transplantation. Medical Faculty. RWTH Aachen University. University Hospital Aachen) ; Universitat Autònoma de Barcelona
Assessment of telomere length (TL) in peripheral blood leukocytes is part of the diagnostic algorithm applied to patients with acquired bone marrow failure syndromes (BMFSs) and dyskeratosis congenita (DKC). [...]
2020 - 10.1111/nyas.14248
Annals of the New York Academy of Sciences, Vol. 1466 Núm. 1 (2020) , p. 93-103  
Detailed record - Creative Commons
5.
4 p, 227.0 KB Unique clinico-biological, genetic and prognostic features of adult early T-cell precursor acute lymphoblastic leukemia / Genescà, Eulàlia (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Morgades, Mireia (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Montesinos, P. (Hospital Universitari i Politècnic La Fe & CIBERONC. Instituto Carlos III) ; Barba, Pere (Hospital Universitari Vall d'Hebron) ; Gil, C. (Clinical Hematology Service. Hospital General de Alicante) ; Guàrdia, R. (Clinical Hematology Service. Hospital Josep Trueta-ICO) ; Moreno, M.J. (Clinical Hematology Service. Hospital Vírgen de la Victoria) ; Martínez-Carballeira, D. (Clinical Hematology Service. Hospital Universitario Central de Asturias) ; García Cadenas, Irene. (Institut d'Investigació Biomèdica Sant Pau) ; Vives Polo, Susana (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Ribera, Jordi (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; González-Campos, J. (Clinical Hematology Service. Hospital Vírgen del Rocío) ; González Gil, Celia (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Zamora, Lurdes (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Ramírez, J.L. (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Díaz-Beya, M. (Clinical Hematology Service. Hospital Clínic de Barcelona) ; Mercadal, S. (Clinical Hematology Service. Hospital Duran i Reynals-ICO. Hospitalet del Llobregat) ; Artola, M.T. (Clinical Hematology Service. Hospital Universitario de Donostia) ; Cladera, A. (Clinical Hematology Service. Hospital Son Llàtzer) ; Tormo, M. (Clinical Hematology Service. Hospital Clínico de Valencia) ; Bermúdez, A. (Clinical Hematology Service. Hospital Marqués de Valdecilla) ; Vall-Llovera, F. (Clinical Hematology Service. Hospital Mútua de Terrassa) ; Martínez, P. (Clinical Hematology Service. Hospital 12 de Octubre) ; Amigo, M.L. (Clinical Hematology Service. Hospital Morales Meseguer) ; Monsalvo, S. (Clinical Hematology Service. Hospital Gregorio Marañón) ; Novo, A. (Clinical Hematology Service. Hospital Son Espases) ; Cervera, M. (Clinical Hematology Service. Hospital Joan XXIII) ; García-Guiñon, A. (Clinical Hematology Service. Hospital Arnau de Vilanova) ; Junca, Jordi (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Ciudad, J. (Centro de Investigación del Cáncer (IBMCC-CSIC/USAL). Hospital Clínico Universitario de Salamanca. Instituto Bio-Sanitario de Salamanca. CIBERONC) ; Orfao, A. (Centro de Investigación del Cáncer (IBMCC-CSIC/USAL). Hospital Clínico Universitario de Salamanca. Instituto Bio-Sanitario de Salamanca. CIBERONC) ; Ribera, Jose-Maria (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Universitat Autònoma de Barcelona
2020 - 10.3324/haematol.2019.225078
Haematologica, Vol. 105 Núm. 6 (january 2020) , p. E294-E297  
Detailed record - Creative Commons
6.
14 p, 3.0 MB Different methylation signatures at diagnosis in patients with high-risk myelodysplastic syndromes and secondary acute myeloid leukemia predict azacitidine response and longer survival / Cabezón, Marta (Universitat Autònoma de Barcelona. Departament de Medicina) ; Malinverni, Roberto (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Bargay, J. (Hospital Son Llàtzer. Hematology Service) ; Xicoy, Blanca (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Marcé, Silvia (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Garrido, A. (Institut d'Investigació Biomèdica Sant Pau) ; Tormo, M. (Hospital Clínico de Valencia. Hematology Service) ; Arenillas, Leonor (Hospital del Mar (Barcelona)) ; Coll, R. (ICO Girona - Hospital Josep Trueta. Hematology Service) ; Borras, J. (Hospital Son Llàtzer. Hematology Service) ; Jiménez, María José (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Hoyos Colell, Montserrat (Institut d'Investigació Biomèdica Sant Pau) ; Valcárcel, David (Hospital Universitari Vall d'Hebron) ; Escoda, L. (Hospital Joan XXIII. Hematology Service) ; Vall-Llovera, F. (Hospital Mútua de Terrassa. Hematology Service) ; Garcia, A. (Hospital Arnau de Vilanova. Hematology Service) ; Font, L. L. (Hematology Service, Hospital Verge de La Cinta, Tortosa, Spain) ; Rámila, E. (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ; Buschbeck, Marcus (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Zamora, Lurdes (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras)
Epigenetic therapy, using hypomethylating agents (HMA), is known to be effective in the treatment of high-risk myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) patients who are not suitable for intensive chemotherapy and/or allogeneic stem cell transplantation. [...]
2021 - 10.1186/s13148-021-01002-y
Clinical Epigenetics, Vol. 13 (january 2021)  
Detailed record
7.
18 p, 292.6 KB Spanish Guidelines for the use of targeted deep sequencing in myelodysplastic syndromes and chronic myelomonocytic leukaemia / Palomo Sanchís, Laura (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Ibáñez, Mariam (Universidad CEU Cardenal Herrera) ; Abáigar, María (Cancer Research Centre (IBMCC-CIC; Univ. of Salamanca-CSIC)) ; Vázquez, Iria (Navarra Institute for Health Research (IdiSNA)) ; Álvarez, Sara (Genómica y Medicina, S.L) ; Cabezón, Marta (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Tazón-Vega, Bárbara (Universitat Autònoma de Barcelona. Departament de Medicina) ; Rapado, Inmaculada (Centro de investigación Biomédica en Red Cáncer (CIBERONC)) ; Fuster-Tormo, Francisco (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Cervera, José (Hospital Universitario y Politécnico La Fe) ; Benito, Rocío (Cancer Research Centre (IBMCC-CIC; Univ. of Salamanca-CSIC)) ; Larrayoz, María J. (Navarra Institute for Health Research (IdiSNA)) ; Cigudosa, Juan C. (Genómica y Medicina, S.L) ; Zamora, Lurdes (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Valcárcel, David (Universitat Autònoma de Barcelona. Departament de Medicina) ; Cedena, María T. (Centro de investigación Biomédica en Red Cáncer (CIBERONC)) ; Acha, Pamela (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Hernández-Sánchez, Jesús M. (University of Salamanca (USAL)) ; Fernández-Mercado, Marta (University of Navarra) ; Sanz, Guillermo (Instituto Carlos III) ; Hernández Rivas, Jesús María (Hospital Universitario de Salamanca) ; Calasanz, María J. (Navarra Institute for Health Research (IdiSNA)) ; Sole, F (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Such, Esperanza (Universidad CEU Cardenal Herrera)
The landscape of medical sequencing has rapidly changed with the evolution of next generation sequencing (NGS). These technologies have contributed to the molecular characterization of the myelodysplastic syndromes (MDS) and chronic myelomonocytic leukaemia (CMML), through the identification of recurrent gene mutations, which are present in >80% of patients. [...]
2019 - 10.1111/bjh.16175
British Journal of Haematology, Vol. 188 (october 2019) , p. 605-622  
Detailed record - Creative Commons
8.
14 p, 1.9 MB Impact of mutational studies on the diagnosis and the outcome of high-risk myelodysplastic syndromes and secondary acute myeloid leukemia patients treated with 5-azacytidine / Cabezón, Marta (Universitat Autònoma de Barcelona. Departament de Medicina) ; Bargay, Joan (Hospital Son Llàtzer, Mallorca) ; Xicoy, Blanca (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; García, Olga (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Borrás, Josep (Hospital Son Llàtzer, Mallorca) ; Tormo, Mar (Hospital Clínic de Valencia) ; Marcé, Sílvia (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Pedro, Carme (Hospital del Mar, Barcelona) ; Valcárcel, David (Hospital Universitari Vall d'Hebron) ; Jiménez, Maria José (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Guàrdia, Ramón (ICO Girona-Hospital Josep Trueta, Girona) ; Palomo Sanchís, Laura (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Brunet, Salut (Institut d'Investigació Biomèdica Sant Pau) ; Vall-Llovera, Ferran (Hospital Mútua de Terrassa) ; Garcia, Antoni (Hospital Arnau de Vilanova (Lleida)) ; Feliu, Evarist (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Zamora, Lurdes (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Universitat Autònoma de Barcelona
Myelodysplastic syndromes (MDS) are stem cell disorders caused by various gene abnormalities. We performed targeted deep sequencing in 39 patients with high-risk MDS and secondary acute myeloid leukemia (sAML) at diagnosis and follow-up (response and/or relapse), with the aim to define their mutational status, to establish if specific mutations are biomarkers of response to 5-azacytidine (AZA) and/or may have impact on survival. [...]
2018 - 10.18632/oncotarget.25046
Oncotarget, Vol. 9 (april 2018) , p. 19342-19355  
Detailed record - Creative Commons
9.
15 p, 2.2 MB Targeted deep sequencing improves outcome stratification in chronic myelomonocytic leukemia with low risk cytogenetic features / Palomo Sanchis, Laura (Universitat Autònoma de Barcelona. Departament de Bioquímica i Biologia Molecular) ; Garcia, Olga (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Arnan, Montse (ICO-Hospital Duran i Reynals. Hematology Service) ; Xicoy, Blanca (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Fuster García, Francisco (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Cabezón, Marta (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Coll, Rosa (ICO-Hospital Josep Trueta. Hematology Service) ; Ademà Llobet, Vera (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Grau Cat, Javier (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Jiménez, Maria-José (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Pomares, Helena (ICO-Hospital Duran i Reynals. Hematology Service) ; Marcé, Sílvia (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Mallo, Mar (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Millá, Fuensanta (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Alonso, Esther (ICO-Hospital Duran i Reynals. Hematology Service) ; Sureda, Anna (ICO-Hospital Duran i Reynals. Hematology Service) ; Gallardo Giralt, David (ICO-Hospital Josep Trueta. Hematology Service) ; Feliu, Evarist (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Ribera, Jose-Maria (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Solé, Francesc (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Zamora, Lurdes (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras)
Clonal cytogenetic abnormalities are found in 20-30% of patients with chronic myelomonocytic leukemia (CMML), while gene mutations are present in >90% of cases. Patients with low risk cytogenetic features account for 80% of CMML cases and often fall into the low risk categories of CMML prognostic scoring systems, but the outcome differs considerably among them. [...]
2016 - 10.18632/oncotarget.10937
Oncotarget, Vol. 7, Num. 35 (August 2016) , p. 57021-57035  
Detailed record - Creative Commons

Research literature 3 records found  
1.
207 p, 4.7 MB Implicación de las alteraciones en el número de copias en el pronóstico y progresión de la leucemia aguda linfoblástica de línea B del adulto / Ribera Salas, Jordi ; Zamora Plana, Lurdes, dir. ; Ribera Santasusana, J. M., (José María) dir. ; Universitat Autònoma de Barcelona. Departament de Medicina
El 75% de los pacientes con leucemia aguda linfoblástica (LAL) tiene alteraciones cromosómicas recurrentes (numéricas o estructurales). Dichas anomalías (alteraciones primarias) tienen valor pronóstico independiente de otras variables y ello se tiene en cuenta para administrar un tratamiento adaptado al riesgo de cada leucemia. [...]
Approximately, 75% of acute lymphoblastic leukemia (ALL) patients show recurrent chromosomal abnormalities (numerical and structural). These are primary alterations that have been extensively related to patients' prognosis. [...]
[Barcelona] : Universitat Autònoma de Barcelona, 2017.  
Detailed record - Creative Commons
2.
173 p, 2.0 MB Caracterización genética de la leucemia mielomonocítica crónica de bajo riesgo citogenético / Palomo Sanchis, Laura ; Zamora Plana, Lurdes, dir. ; Solé Ristol, Francisco, dir. ; Ponte Marull, Immaculada, dir. ; Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular
La leucemia mielomonocítica crónica (L12C) es una entidad que presenta una gran heterogeneidad a nivel clínico, morfológico y genético. El 70-75% de los pacientes con L12C presenta un cariotipo normal al diagnóstico y hasta el 80% de los pacientes se clasifica en el grupo citogenético de bajo riesgo (cariotipo normal o pérdida aislada del cromosoma Y). [...]
La leucemia mielomonocítica crónica (LMMC) es una entidad que presenta una gran heterogeneidad a nivel clínico, morfológico y genético. El 70-75% de los pacientes con LMMC presenta un cariotipo normal al diagnóstico y hasta el 80% de los pacientes se clasifica en el grupo citogenético de bajo riesgo (cariotipo normal o pérdida aislada del cromosoma Y). [...]
[Barcelona] : Universitat Autònoma de Barcelona, 2017.  
Detailed record - Creative Commons
3.
138 p, 2.1 MB Caracterització biològica de la trombocitèmia essencial i la policitèmia vera / Zamora Plana, Lurdes ; Florensa, L., dir. (Hospital del Mar. Servei de Patologia) ; Espinet i Solà, Blanca, dir. (Hospital del Mar. Servei de Patologia)
El concepte de síndromes mieloproliferatives cròniques (SMPC) engloba un conjunt d'entitats hematològiques amb característiques clíniques i evolutives molt similars i d'etiopatogènia probablement comú. [...]
Essential thrombocythemia (ET) and polycythemia vera (PV) are chronic myeloproliferative disorders (MPD) arising from the clonal expansion of a pluripotential stem cell. Specific genetic lesions have not been recognized for both disorders, so, diagnostic criteria still are based on the presence or absence of particular clinical and laboratory features In recent years, there have been attempts to find new positive criteria that could help in the diagnosis of ET and PV, such as spontaneous in vitro colony formation of erythroid and megakaryocytic progenitors, conventional cytogenetics, fluorescence in situ hybridization techniques and analysis of X-chromosome inactivation patterns (XCIPs). [...]
Bellaterra : Universitat Autònoma de Barcelona, 2006  
Detailed record -

See also: similar author names
2 Zamora, L.
1 Zamora, Lluís
Interested in being notified about new results for this query?
Set up a personal email alert or subscribe to the RSS feed.
UAB Digital Repository of Documents :: Search :: Submit :: Personalize :: Help
Powered by Invenio v1.1.6
Maintained by ddd.bib@uab.cat  :: Metadata license:
Working with